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Abstract
Background: Better understanding of drug resistance patterns in HIV-infected children on antiretroviral therapy
(ART) is required to inform public health policies in high prevalence settings. The aim of this study was to
characterise the acquired drug resistance in HIV-infected children failing first-line ART in a decentralised rural HIV
programme.
Methods: Plasma samples were collected from 101 paediatric patients (≤15 yrs of age) identified as failing ART.
RNA was extracted from the plasma, reverse transcribed and a 1.3 kb region of the pol gene was amplified and
sequenced using Sanger sequencing protocols. Sequences were edited in Geneious and drug resistance mutations
were identified using the RegaDB and the Stanford resistance algorithms. The prevalence and frequency of
mutations were analysed together with selected clinical and demographic data in STATA v11.
Results: A total of 101 children were enrolled and 89 (88%) were successfully genotyped; 73 on a non-nucleoside
reverse-transcriptase inhibitor (NNRTI)-based regimen and 16 on a protease inhibitor (PI)-based regimen at the time
of genotyping. The majority of patients on an NNRTI regimen (80%) had both nucleoside reverse-transcriptase
inhibitor (NRTI) and NNRTI resistance mutations. M184V and K103N were the most common mutations amongst
children on NNRTI-based and M184V among children on PI-based regimens. 30.1% had one or more thymidine
analogue mutation (TAM) and 6% had ≥3 TAMs. Only one child on a PI-based regimen harboured a major PI
resistance mutation.
Conclusions: Whilst the patterns of resistance were largely predictable, the few complex resistance patterns seen
with NNRTI-based regimens and the absence of major PI mutations in children failing PI-based regimens suggest
the need for wider access to genotypic resistance testing in this setting.
Background
Globally and within South Africa, access to paediatric anti-
retroviral therapy (ART) has increased significantly and this
in turn has impacted on mortality and morbidity among
HIV-infected children [1-5]. The face of paediatric HIV is,
thus, now that of a chronic disease rather than one that will
necessarily result in death or serious morbidity [6]. The
challenge of long-term adherence to ART in children gives
rise to the potential for the emergence of drug resistance
leading to treatment failure [7,8]. In resource–limited
settings, there are challenges to the implementation,
long-term effectiveness and sustainability of ART pro-
grammes where limited laboratory capacity to monitor
treatment effectiveness and a lack of paediatric antiretro-
viral (ARV) formulations are notable restrictions [9]. There
is some evidence that outcomes for children in rural areas
of South Africa are poorer than those in urban areas
[10]. In addition, socio-economic and psychosocial factors
impact on optimal adherence and access to ART which in
turn accelerate the development of drug resistance [11].
Without optimal management, patients can remain on
failing regimens for long periods leading to the accumula-
tion of drug resistance mutations, which can then confer
cross-resistance to drugs in the same class and compromise
future therapy [7,8]. The number of drugs available in South
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Africa is limited and there are currently no third-line
options available to children failing therapy.
The data on ARV resistance in children in South Africa
are relatively limited and have largely been restricted to
urban hospital-based programmes, which may not be rep-
resentative of all programmes [12-18]. Of the seven pub-
lished studies in South Africa that used genotyping to
determine the level of resistance the largest study included
51 genotypes and none was from a rural setting [12-18].
Continuing surveillance of drug resistance is important
not only to guide paediatric ART policies but also to ex-
plore whether there might be a role for genotypic resist-
ance testing within clinical care of HIV-infected children
in this region. This is important because evidence-based
management of children will ensure the longevity of their
ART regimens. We have previously reported high levels
of drug resistance in adults failing first-line ART in our
decentralised, primary health care programme [19]. The
primary objective of this study was to determine the fre-
quency and patterns of resistance mutations in children
failing first-line ART.
Results
Participants
Of the approximately 1653 children (≤15 years) who
were initiated in and are currently active in the ART
program, we identified a total of 101 children with evi-
dence of virological failure on first-line ART and en-
rolled them between August 2011 and December 2012.
The median time between last viral load result and
genotyping was 3.1 months (IQR 1.4 - 7.0). Of the 101
samples, genotyping using the SATuRN genotyping
method was successful in 89 cases (88.1%) (Figure 1).
The mean viral load of the successful genotypes was
4.92 log10 copies/ml ± 5.3 (2.35-6.18log10 copies/ml).
Twelve samples (11.9%) failed to amplify by PCR and
were subsequently submitted for viral load quantification.
Of these, six patients had a viral load at the time of geno-
typing of >1000copies/ml (mean = 3.77log10 copies/ml;
range = 3.0-4.4 log10 copies/ml) but failed to amplify while
five were suppressed with viral loads <1000copies/ml.
There was insufficient sample to perform viral load quan-
tification for one patient’s sample.
The characteristics of the children with a genotype are
shown in Table 1. Sixteen children (18.0%) were on a first-
line protease inhibitor-based regimen and 73 (82.0%) were
on an NNRTI-based regimen at the time of genotyping.
The overall median duration of ART was 3.3 years (IQR
2.5 - 4.4) and the median duration of ART failure was
1.8 years (IQR 0.8 - 2.4).
Of the 89 children genotyped, 41 (46.1%) had, on at least
one occasion, successfully suppressed viremia to <1000
copies/ml. The median duration on ART was slightly
longer for those children on an NNRTI-based regimen
compared to those on a PI-based regimen (3.4 years vs.
2.7 years) but the duration of ART failure was broadly
similar between the same two groups (Table 2). We noted
that the clinical and demographic characteristics of pa-
tients who suppressed compared with those that never
suppressed (n = 48) was comparable (Table 3). The major-
ity of patients in both groups were on 3TC-D4T-EFV
both at initiation and at the time of genotyping
(Table 3). Patients who had not suppressed were on a
failing regimen for a statistically shorter (p = 0.04)
period of time (median = 1.6 yrs; IQR = 1.4 yrs) compared
with those that did suppress viremia (median = 1.9 yrs;
IQR = 1.8 yrs). In addition, children who managed to
suppress their viremia during treatment were older at
the time of genotyping (p = 0.02) compared with those
that never suppressed (Table 3). As expected, the median
viral load at the time of genotyping of patients who
never suppressed (median = 4.7 log10 cp/ml; IQR = 0.9
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Figure 1 Flow chart showing children enrolled at PHC clinics and outcomes of genotyping.
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log10 cp/ml) was significantly higher (p = 0.02) than those
that did (median = 3.9 log10 cp/ml; IQR = 4.7 log10 cp/ml).
Drug resistance mutations (DRM)
All of the sequences accepted for analysis were deemed of
high quality having passed all quality and contamination
tests as described. The HIV isolates from all patients suc-
cessfully genotyped were identified as HIV-1 subtype C
variants. Of the 89 genotypes, 81 (91.0%) demonstrated at
least one DRM while 8 (9.0%) had no DRM (Table 4). For
those on an NNRTI-based regimen, the majority of geno-
types had both NRTI and NNRTI mutations. Thymidine
analogue mutations (TAMs) were detected in 22 (24.7%)
genotypes, while three or more TAMs were detected in
only four of 89 genotypes (4.5%). The Q151M complex
(a multinucleoside resistance mutation) was present in
two genotypes, one from a child on an NNRTI-based
regimen and one from a child on a PI-based regimen.
Only one child on a PI-based regimen (1/16, 6.3%) har-
bored a major protease mutation and the most common
pattern for children on PI-based regimens was the M184V
mutation alone (Table 4).
An analysis of the genotypic susceptibility scores (GSS)
of patients revealed that the median GSS for patients on a
PI regimen (median = 2.0, IQR = 1.25) was higher as com-
pared with those on an NNRTI-regimen (median = 1.0,
IQR = 0.5). The majority (n = 12, 75%) of the patients on
a PI-regimen, had GSS scores ≥2 while only 10 (14%) of
those on an NNRTI-based regimen had comparable scores.
Discussion
In this study, we determined the frequency and patterns
of drug resistance mutations in children failing first-line
ART in a rural primary health care ART programme
where care is delivered largely by nurses and counselors.
For older children on NNRTI-based regimens, drug re-
sistance mutations were detected in the majority. Whilst
in most cases the mutations would be unlikely to signifi-
cantly compromise a second-line regimen based on a
ritonavir-boosted PI, five patients had complex mutation
Table 1 Demographic and clinical characteristics of the
89 children with a genotype
Characteristic Outcome
Gender, male, n (%) 53 (59.6)
At ART initiation
Age, years, median (IQR) 7 (3.7-9.6)
Number of children per age group n(%)
0-3 years 17 (23)
4-9 years 37 (50)
10-15 years 20 (27)
Viral load, log10 copies/ml, median (IQR) 4.0 (3.7-4.7)
CD4+ cell count, cells/μl, median (IQR) 286 (112–560)
By Age category:
0 - 2 yrs (n = 3) 817 (31–1564)
>2 – 5 yrs (n = 29) 469 (194–619)
>5 yrs (n = 38) 200 (69–363)
ART regimen, n (%)
d4T/3TC/EFV 64 (71.9)
d4T/3TC/LPVr 12 (13.5)
ABC/3TC/EFV 8 (8.9)
ABC/3TC/LPVr 4 (4.5)
AZT/3TC/EFV 1 (1.1)
At genotyping
Age, years, median (IQR) 10.2 (7.7 – 12.9)
Number of children per age group n(%)
0-3 years 4 (4.5)
4-9 years 38 (42.7)
10-15 years 47 (52.8)
Viral load prior to genotyping*, log10
copies/ml, median (IQR)
4.2 (3.8-4.8)
CD4+ cell count prior to genotyping*,
cells/μl,
460 (228–769)
median (IQR)
By Age category: 2339 (1621–2538)
0 - 2 yrs (n = 4 ) 685 (442–956)
2 – 5 yrs (n = 37) 295 (147–564)
>5 yrs (n = 47)
ART regimen at time of genotyping, n (%)
d4T/3TC/EFV 58 (65.2)
d4T/3TC/LPVr 8 (8.9)
ABC/3TC/EFV 14 (15.7)
ABC/3TC/LPVr 8 (8.9)
AZT/3TC/EFV 1 (1.1)
Duration of ART, years, median (IQR) 3.3 (2.5-4.4)
Duration of ART failure†, years, median (IQR) 1.8 (0.8-2.4)
Table 1 Demographic and clinical characteristics of the
89 children with a genotype (Continued)
Time between last viral load and genotype,
months, median (IQR)
3.1 (1.4-7.0)
History of ART substitution#, yes, n (%) 12 (13.5)
Key:
d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; LPVr, lopinavir/ritonavir; ABC,
abacavir; AZT, zidovudine; ART, antiretroviral therapy; IQR, interquartile range.
*Last measurements recorded prior to date of genotype.
†Duration of antiretroviral failure was estimated from the date of the first viral
load >1000 copies/ml to date of genotype, unless there was a viral load <50
copies/ml in-between, in which case the time was estimated from the next
viral load >1,000 copies/ml. If there was no viral load ≤1,000 copies/ml then
time was calculated from date of ART initiation.
#Substitutions included changes of single drugs due to toxicity or
guideline changes.
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patterns (three or more TAMs or Q151M complex) that
might substantially limit the future activity of the NRTI
class of drugs. In contrast, the younger children on PI-
based regimens more often had no drug resistance mu-
tations (six of 16 cases) and all but one had an absence
of major protease mutations. This suggests a potential
need for drug resistance genotyping, particularly in this
group on PI-based regimens, to determine the appropriate-
ness of regimen switch and to preserve first-line regimens
where possible.
These data represent one of the largest drug resistance
studies of paediatric patients failing ART undertaken
thus far in South Africa [12-18]. In addition, this study
was unique in being from a rural decentralized primary
health care programme where the delivery of ART to
adults and children has scaled up rapidly. The character-
istics of the children included in the study highlight
some of the challenges of ART delivery in this setting,
with very long time spent on failing regimens, a finding
also reported amongst our adults on ART [19]. This sug-
gests not only challenges to long-term adherence but
also deficiencies in following the protocol for virological
monitoring and switch to second-line ART guidelines.
Problems with delayed switching have been well docu-
mented in South Africa [1,9,17] and these may be par-
ticularly problematic with children as many nurses and
counselors are not confident managing paediatric ART
and receive insufficient support and training in these is-
sues. Some of the barriers to adherence in this setting
are complex and difficult to address with the resources
available within the health system. Furthermore, in rural
areas with largely paper-based systems, results may sim-
ply be lost or misfiled and therefore overlooked.
First-line ART in South Africa using NNRTI-based
regimens is challenging given the low genetic barrier of
currently available drug options such as efavirenz and
nevirapine and the fact that only one or two key DRMs
are required to confer high-level resistance or cross-
resistance to a drug class [20]. High-level resistance mu-
tations and cross-resistance severely compromises future
ART options, a dire consequence for paediatric patients
who require lifelong ART. We detected high levels of drug
resistant mutations in the group failing NNRTI-based
regimens. The majority (80%) had both NRTI and NNRTI
resistance mutations. The proportion that had complex
Table 2 Characteristics of children on NNRTI-based and PI-based regimens (based on regimen at time of genotype)
NNRTI (n = 73) PI (n = 16)
At ART initiation
Age, years, median (IQR)** 7.6 (5.2-10) 1.5 (0.7-3.8)
CD4+ cell count, cells/μl, median (IQR)* 256 (108–477) 647 (112–817)
Viral load, log10 copies/ml, median (IQR) 3.9 (3.7-4.2) 4.7 (4.7-4.7)
At Genotyping
Age at genotyping, years, median (IQR) 11.4 (8.9-13.4) 5.0 (2.7-7.5)
CD4+ cell count prior to genotyping, cells/μl, median (IQR)** 379 (167–668) 762 (603–1123)
Viral load prior to genotyping, log10 copies/ml, median (IQR) 4.3 (3.8-4.8) 4.3 (3.8-5.2)
Comparative measures
Duration of ART, years, median (IQR) 3.4 (2.6-4.5) 2.7 (1.6-4.0)
Duration of ART failure, years, median (IQR) 1.8 (0.9-2.4) 1.6 (0.8- 2.3)
Time between last viral load and genotyping, months, median (IQR) 3.3 (1.6-7.1) 3.0 (1.1-4.85)
Key: Difference in means at a 1% (**) or 5% (*) level of significance using the Student’s T-Test.
Table 3 Comparison of outcomes for patients who
successfully suppressed viremia to <1000cp/ml with
patients who were unable to suppress viral replication
while on treatment
Suppressed
(n = 41)
Never suppressed
(n = 48)
Gender:
Male 23 30
At initiation:
Age, years, median (IQR) 6.9 (4.4-9.8) 7.1 (3.2-9.6)
Viral load, log10 cp/ml,
median (IQR)
3.8 (3.4-4.7) 4.2 (3.7-4.7)
CD4, cells/μl, median (IQR) 290 (136–563) 281 (89–560)
Regimen
3TC-D4T-EFV 33 31
3TC-D4T-LPV/r 6 6
3TC-ABC-EFV 1 7
3TC-ABC-LPV/r 0 4
3TC-AZT-EFV 1 0
At genotyping:
Age, years, median (IQR)* 11.1 (8.5-13.1) 9.8 (5.6-12.3)
Key: *Statistical significance (T-test, P<0.05).
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NRTI resistance patterns, such as three or more TAMs or
Q151M complex, was lower (5.5%) than another recent
study of 38 children on ART from the same province where
39% had three or more TAMs [17] despite a shorter dur-
ation (median = 2.8 yrs; IQR = 1.9- 2.3 yrs) on ART com-
pared with our cohort (median = 3.3 yrs; IQR = 2.5-4.4 yrs).
This suggests that the majority of children failing first-line
NNRTI-based regimens in our cohort should retain
susceptibility to a second-line regimen consisting of
two alternative NRTIs and a ritonavir-boosted PI.
It was noteworthy that only one of 17 children on a
PI-based regimens had a major PI resistance mutation.
The low prevalence of PI mutations has been previously
described in a number of manuscripts [17,21,22] This
does raise the possibility of differential adherence to differ-
ent components of the ART regimen (lopinavir/ritonavir
syrup can be poorly tolerated), to problems with dosing
of lopinavir/ritonavir syrup or possibly to drug-drug
interactions particularly for those co-infected with TB,
all issues we were unable to explore in detail for this
study but which are subject to on-going research.
The finding that around nine in ten children with viro-
logical failure had at least one drug resistance mutation is
consistent with other studies from South Africa [22-24]
and a systematic review of studies from low- and middle-
income countries, which reported a pooled proportion of
90% of children on ART with any DRM [8] The propor-
tion with TAMs (23%) was similar to that seen in a similar
paediatric programme in the Western Cape (19%) [22],
although lower than the 56% reported in a systematic
review of first-line failure of paediatric patients [8]. The
proportion with TAMs was surprisingly low given the long
duration of virological failure, and was also lower
than the 40% reported from adults in our programme
with a similar duration of ART and similar time on a
failing regimen in an adult cohort from the same region
[19]. This might suggest that adherence levels were
either too low or too variable for the accumulation of
TAMs over time. Alternatively, there was differential
adherence to components of the regimen, with avoid-
ance or suboptimal dosing of stavudine (d4T). The
lack of major PI mutations in the young children on
LPV/r-based regimens is consistent with other studies
from the region which have shown PI mutations to
be much more commonly associated with full dose
ritonavir-based regimens [16,21-23].
Currently our genotyping costs are approximately 50
US$ at reagents cost and less than 100US$ when staff
and transport costs are added on. The normal cost of
genotyping is 250–300 US$ in the public sector. In order
to facilitate large-scale genotyping and in the interest of
reducing costs, we did not perform a pre-genotype con-
firmatory viral load, yet we successfully genotyped 88%
(89/101) of our cohort. Our genotyping system and re-
agents are likely to be affordable to upper middle-
income countries like South Africa and Botswana but
further cost reductions would be required to make drug
resistance testing affordable in lower middle-income and
low income countries within Africa. An additional fea-
ture of our study was that genotypes directed subse-
quent clinical care where a doctor, social worker and
other clinic staff managed patients from enrolment to
implementing an intervention post-genotyping as was
carried out in an adult cohort from the same area. The
Table 4 The frequency of major drug resistance
mutations and resistance complexes associated with PIs,
NRTIs and NNRTIs of the 89 genotyped patients
NNRTI-based
regimen (n = 73)
PI-based regimen
(n = 16)
NNRTI mutations Number Percentage Number Percentage
Any NNRTI DRM 60 82.2 4 25.0
L100I 5 6.9 0 0
K101EP 6 8.2 0 0
K103NRS 46 63.0 2 12.5
V106M 23 31.5 2 12.5
V108I 7 9.6 1 6.3
Y181C 2 2.7 0 0
Y188HCL 7 9.6 1 6.3
G190AS 9 12.3 1 6.3
P225H 14 19.2 0 0
M230L 3 4.1 0 0
NRTI mutations
Any mutation 63 86.3 10 62.5
M41L 7 9.6 0 0
K65NR 4 5.5 1 6.3
D67NG 8 11.0 0 0
K70ER 7 9.6 0 0
L74VI 4 5.5 1 6.3
Y115F 3 4.1 2 12.5
M184VI 60 82.2 10 62.5
L210W 1 1.4 0 0
T215FYI 9 12.3 0 0
K219QREN 5 6.9 0 0
Any TAMS 22 30.1 0 0
1 TAM 11 15.1 0 0
2 TAMs 7 9.6 0 0
≥3 TAMs 4 5.5 0 0
Q151M complex 1 1.4 1 6.3
PI mutations
Any PI mutation 0 0 1 6.3
V82A 0 0 1 6.3
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results from our study addressed three of the ten goals of
the Department of Health 2010 ART Guidelines in that
we present a means of achieving the best outcomes for
HIV-infected patients receiving ART in a cost-effective
manner; we employ existing infrastructure, that of a
decentralised rural public health clinic facility for patient
management; and by identifying DRMs early we ensure
patient retention on lifelong ART by instituting early in-
terventions to halt ART failure and prevent morbidity and
mortality.
Interpretation of these data should be subject to some
limitations of the study. This was a cross-sectional study
and whilst we identified as many children with first-line
ART failure as possible, we were unable to accurately esti-
mate what proportion of all children on ART had viro-
logical failure and we cannot be certain that we included
all children meeting the eligibility criteria. Further, we did
not have accurate information on prior exposure to
pMTCT regimens either in the mother or infant therefore
have no means of assessing its impact on the spectrum of
DRMs we observed in this cohort. We can speculate that
the patterns of NNRTI mutations we observed are sug-
gestive of and may arise from pMTCT exposure, however
we cannot determine with certainty from our data
whether DRMs in these children were acquired or trans-
mitted via MTCT. We note this as a limitation of the
present study. Although these data represent the lar-
gest group of genotypes for children failing first-line
ART in South Africa, the numbers remain small. This
highlights the need for collaborative studies and surveil-
lance from multiple representative sites in order to
inform national policies. The data regarding protease
inhibitor resistance mutations could be limited by
exploring only the protease gene and it is possible
that we missed mutations at other sites, e.g. Gag cleavage
sites [25].
Conclusions
In conclusion, this study has demonstrated that the
spectrum of drug resistance mutations in this rural cohort
is varied. The concerning prevalence of high-level re-
sistance mutations particularly the frequency of TAMs
amongst this paediatric cohort is an indicator of the
time these patients spent on a failing regimen. This
highlights the need for timely identification of patients
failing ART and the implementation of early interven-
tions be it drug switches or effective, reinforced, adher-
ence counseling with appropriate follow-up. The use of
genotyping, without a concurrent viral load, was efficient
at identifying patients failing as a result of resistance
mutations, determining the resistance profile of the patients
and directing interventions for patient management.
In this way, treatment options can be extended, a critical
consideration for paediatric patients.
Methods
Setting
The study was conducted in the predominantly rural
Hlabisa health sub-district in northern KwaZulu-Natal,
South Africa. The programme, delivered by the Depart-
ment of Health with support from the Africa Centre for
Health and Population Studies (www.africacentre.ac.za),
has been described previously [1,23,26]. HIV treatment
and care is fully devolved to 17 primary health care
(PHC) clinics and delivered largely by nurses and coun-
sellors, with medical officers visiting clinics on a weekly
or fortnightly basis. The programme adheres to national
ART guidelines. At the time of the study, children eli-
gible for ART aged 0–3 years (or weight under 10 kg)
were commenced on a protease inhibitor (PI)-based
regimen whereas children older than 3 years were com-
menced on a non-nucleoside reverse-transcriptase in-
hibitor (NNRTI)-based regimen. Viral load monitoring
was scheduled six-monthly, although precise timing of
viral load measurements was quite variable. Treatment
of HIV-infected children was scaled up from late 2004
but accelerated in 2008 [1,23,27].
Study design
This cross-sectional study enrolled children (≤ 15 years of
age) who had been receiving ART for more than 12
months with evidence of virological failure, defined as two
consecutive viral loads >1000 copies/ml. Children with
virological failure were identified from all 17 clinics both
passively, during routine clinic visits, and actively, through
interrogation of the programme database, which is housed
at the Africa Centre and also by looking at all paediatric
case files at the clinics. At the same time, the files of any
children not eligible for the study but who were overdue
for a routine viral load measurement were noted and a
blood sample, to be taken at the next clinic visit, was
requested. Single drug substitutions were allowed for
toxicity or in the event of guideline changes. Any child
meeting the enrolment criteria was subsequently enrolled.
A medical officer enrolled all children and, either a parent
or guardian provided the written informed consent. Demo-
graphic and clinical information were collected from clin-
ical charts at the time of enrolment and a venous blood
sample (4 ml EDTA tube) was collected on the same day.
Laboratory methods
Blood specimens, collected at the primary health care
clinics, were transported from the Africa Centre to the
Durban laboratory (~200 km away) on the same day of
collection. Samples were received at the laboratory, re-
corded in a Laboratory Information Management
System (LIMS) and the plasma was harvested and stored
at −80°C until use. This blood specimen was collected
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specifically for resistance genotyping and was not reserved
for viral load testing.
We used the affordable and open access Southern
African Treatment Resistance Network (SATuRN) drug
resistance genotyping system [Manasa et al. in preparation].
Briefly, this is an in-house method that costs approximately
50 US$ at reagent price. In order to keep the costs low, no
viral load was performed before drug resistance genotyping.
Ribonucleic acid (RNA) was extracted using the Qiagen
RNA Mini kit (Qiagen N.V., Venlo, Netherlands) and re-
verse transcribed using the Superscript® III First-Strand
Synthesis kit (Life Technologies, Carlsbad, CA) and RT21
specific primer (CTGTATTTCAGCTATCAAGTCCTTT-
GATGGG). A 1315 bp fragment of the pol gene, covering
all the 99 protease codons and the first 240 codons of the
reverse transcriptase (RT) gene was amplified with the high
fidelity proofreading Platinum® Taq DNA polymerase (Life
Technologies, Carlsbad, CA) and primers MAW26(TTGG
AAATGTGGAAAGGAAGGAC) and RT21 (CTGTATTT
CAGCTATCAAGTCCTTTGATGGG) for the first step
and PRO1 (TAGAGCCAACAGCCCCACCA) and RT20
(CTGCCAATTCTAATTCTGCTTC) for the second step
polymerase chain reaction (PCR). Population sequencing
was performed on successfully amplified PCR products that
were identified by gel electrophoresis and visualized as a
1.3 kb fragment under ultraviolet (UV) light. The PCR
products were cleaned using the PureLink® PCR purifica-
tion kit (Life Technologies, Carlsbad, CA) and were se-
quenced using the Sanger BigDye® terminator sequencing
protocol (Life Technologies, Carlsbad, CA) and four bidir-
ectional primers (RTC1F-ACCTACACCTGTCAACATAA
TTG, RTC2R-TGTCAATGGCCATTGTTTAACCTTTGG,
RTC3F-CACCAGGGATTAGATATCAATATAATGTGC,
and RTC4R-CTAAATCAGATCCTACATACAAGTCA
TCC), and run on an ABI 3130xl genetic analyser (Life
Technologies, Carlsbad, CA), finally generating a consen-
sus sequence spanning 300 amino acids of RT and 99
amino acids of the protease gene. The first 240 codons of
the RT gene cover all currently recognized RT mutations
associated with resistance to available RT inhibitors.
Samples that failed to amplify were submitted for viral
load testing using the Biocentric HIV RNA Charge Virale
method (Biocentric, Bandol, France) with a detection limit
of 50 copies/ml.
Sequence assembly and quality analysis
Sequences were imported into Geneious (Biomatters Ltd,
Auckland, New Zealand), visually edited and deemed high
quality if the quality score was higher than 80% post-
trimming. Once trimmed these fragments were mapped
to a reference strain (Accession# JN665021.1) to create a
contig, which was further assessed for quality and ambigu-
ities before a consensus sequence was extracted. Prior to
the detection of drug resistance mutations (DRM) using
bioinformatics software applications, we submitted each
consensus to the Calibrated Population Resistance Tool
(CPR) (http://hivdb.stanford.edu) for a final quality check.
Sequences were deemed high quality if they had no am-
biguities or insertions/deletions. In order to test for con-
tamination we blasted our sequences against the public
dataset using NCBI blast (http://www.ncbi.nlm.nih.gov/
blast) and against our local database using a BlastServer
application. Sequences were deemed not a contaminant if
the identity to previously genotyped samples was lower
than 98%. Finally, we constructed a maximum likelihood
(ML) phylogenetic tree using phyML with GTR, gamma
and percentage of invariable sites estimated from dataset.
Trees were evaluated with 100 bootstraps and visualized
in FigTree (http://tree.bio.ed.ac.uk/software/figtree/) in
order to identify contamination where sequences cluster
together with low genetic diversity.
Data analysis
All sequences, laboratory results (viral loads, CD4+ cell
counts) and clinical and demographic data were entered
into the SATuRN RegaDB database [28,29]. The database
first identifies the subtype of each sequence using Rega
HIV Subtyping tool version 2 [30,31], and thereafter deter-
mines the effect of DRMs on antiretroviral susceptibility
using the three primary drug resistance interpretation algo-
rithms, developed at Stanford University, Agence nationale
de recherches sur le sida et les hépatitis virales (ANRS) and
the Rega Institute. The amino acid positions on the RT
gene relevant to the NRTI drug resistance mutations were
41, 62, 65, 67, 69, 70, 74, 75, 77, 115, 116, 151, 184, 210,
215 and 219. For the NNRTI drug class we included the
amino acid positions 100, 101, 103, 106, 108, 138, 179, 181,
188, 190, 221, 225, 227 and 230 of the RT gene. Finally, for
the PI drug class we interrogated our sequences using the
following major drug resistance amino acid positions of
the protease gene: 30, 32, 46, 47, 48, 50, 54, 58, 74, 76, 82,
83, 84, 88 and 90. Mutations were coded as DRMs at these
positions based on the IAS mutation list of 2013 [32]. Drug
resistance mutations, clinical measurements and demo-
graphic data were exported from RegaDB for analysis.
Descriptive statistics were used to summarise the
demographic and clinical characteristics. Medians and
the interquartile range (IQR) were calculated for con-
tinuous data. For analysis of drug resistance mutations,
frequency distributions of the major DRMs were derived.
Duration on ART was defined as the number of months
between the date of ART initiation and the date of
genotyping. The “duration of ART failure” was de-
fined as the period from the date of the first viral
load >1000 copies/ml to date of genotyping, unless
there was a viral load <50 copies/ml in between, in
which cases the duration was estimated from the time
of the next available viral load >1000 copies/ml. If
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there was no viral load ≤1000 copies/ml then duration
was calculated from date of ART initiation.
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